1.Title: Inovio (INO) initiates phase 1 study on hepatitis C vaccine – Zacks Equity Research
Summary: Inovio Pharmaceuticals announced on September 4th, 2018 that it had begun a phase 1 study of the first hepatitis C vaccine—GLS-6150—to prevent hepatitis C (HCV) infection. The study is in collaboration with GeneOne Life Science. The study will enroll 24 patients previously cured of HCV. The clinical trial results are expected in 2019. Of note, Inovio also launched a phase I/II study of an HIV vaccine that targets all HIV strains that would control HIV without HIV antiretroviral medications. It’s a long shot for any drug to make it from phase 1 to an effective treatment or protective vaccine but it would be remarkable if these two vaccines proved to be effective.
2. Title: Transplantation of hepatitis C virus (HCV) antibody positive, nucleic acid test negative donor kidneys to HCV negative patients frequently results in seroconversion but not HCV viremia—M. E. de Vera, et. al.
Source: Am J Transplant. 2018 Jul 24. doi: 10.1111/ajt.15031. [Epub ahead of print]
Summary: The study looked at 32 patients who received a hepatitis C (HCV) antibody positive, HCV viral load negative kidney from deceased donors and underwent a kidney transplant. So far, all of the patients who received the HCV antibody positive kidneys became HCV antibody positive but remained HCV viral load negative.
3. Title: Cardiac transplantation from non-viremic hepatitis C donors—S. R. Patel, et. al
Source: J Heart Lung Transplant. 2018 Aug 17. pii: S1053-2498(18)31514-6. doi: 10.1016/j.healun.2018.06.012. [Epub ahead of print]
Summary: In 2017, 14 patients received hepatitis C (HCV) antibody positive, HCV RNA negative hearts from deceased donors and underwent a heart transplant. Over a period of 192 to 377 days, three patients developed HCV antibodies, but no patients tested HCV viral load positive.
4. Title: Cost-effectiveness of transplanting HCV-infected livers into uninfected recipients with preemptive antiviral therapy—E.D. Bethea, et. al.
Summary: In the study, the authors analyzed the costs and benefits of receiving an HCV viral load positive liver for transplantation. The patients who received the HCV positive liver were treated with 12-weeks of DAA therapy.
The cost-effectiveness was based on the model for end-stage liver disease (MELD). The higher the MELD score, the higher the severity of liver disease and the need for a liver transplant. The most substantial cost savings were in the people with the highest MELD score. However, even in patients with low MELD scores, there was a benefit to receiving an HCV-positive liver for transplantation.Share This Page